ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=X  !"#$%&'()*+,=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri General;6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_) #,##0.003._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_) #,##0\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\)#\(#,##0.00_);[RED]\(#,##0.00\)                + ) , *  (8  (  $   ( (8  $        $  $  (   `"$item 5 market for our comm$item 5 market for our comm-1$8item 5 market for our comm-2$vitem 5 market for our comm-3$ػitem 5 market for our comm-4$:item 5 market for our comm-5$item 5 market for our comm-6 index$ advaxis incstatement of operations"period from march 1 2002 i statement of cash flows"supplemental disclosures o"V!supplemental schedule of n$,supplemental schedule of n-1$"0supplemental schedule of n-2$3supplemental schedule of n-3@65 intangible assets8:5 intangible assets-1 =6 accrued expensesA6 accrued expenses-1G6 accrued expenses-2@J10 derivativesawarrantsi warrants-1|p warrants-2s11 stock optionsFz11 stock options-1" ~rothman employment agreeme$rothman employment agreeme-1$rothman employment agreeme-2 15 fair value|15 fair value-115 fair value-2"tcommon stock warrant liabi$ޡcommon stock warrant liabi-1$֥common stock warrant liabi-2$Ψcommon stock warrant liabi-3$lcommon stock warrant liabi-4$common stock warrant liabi-5$common stock warrant liabi-6$ȳcommon stock warrant liabi-7"as adopted pursuant to sec$as adopted pursuant to sec-1Tp-,,      !"#$%&'()*+,3  @@   |E Item 5. Market For Our Common Stock and Related Stockholder Matters. Fiscal2012 Fiscal2011HighLow%First Quarter (November 1-January 31))Second Quarter (February 1- April 30) (1)Third Quarter (May 1 - July 31&Fourth Quarter (August 1 - October 31)Securities Purchase Agreement between the registrant and the purchasers in the private placement (the  SPA ), dated as of October 17, 2007, and Disclosure Schedules thereto. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Securities Purchase Agreement dated February 2, 2006 between the registrant and Cornell Capital Partners, LP. Incorporated by reference to Exhibit 10.01 to Report on Form 8-K filed with the SEC on February 8, 2006.Registration Rights Agreement between the registrant and the parties to the SPA, dated as of October 17, 2007. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Placement Agency Agreement between the registrant and Carter Securities, LLC, dated as of October 17, 2007. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Engagement Letter between the registrant and Carter Securities, LLC, dated August 15, 2007. Incorporated by reference to Exhibit 10.3(a) to Current Report on Form 8-K filed with the SEC on October 23, 2007.Agreement between the registrant and YA Global Investments, L.P. f/k/a Cornell Capital Partners, L.P., dated August 23, 2007. Incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed with the SEC on October 23, 2007.<Memorandum of Agreement between the registrant and CAMHZN Master LDC and CAMOFI Master LDC, purchasers of the Units consisting of common stock, $0.20 warrants, and $0.001 warrants, dated October 17, 2007. Incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Advisory Agreement between the registrant and Centrecourt Asset Management LLC, dated August 1, 2007. Incorporated by reference to Exhibit 10.6 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Share Exchange and Reorganization Agreement, dated as of August 25, 2004, by and among the registrant, Advaxis and the shareholders of Advaxis. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 18, 2004.Security Agreement dated February 2, 2006 between the registrant and Cornell Capital Partners, L.P. Incorporated by reference to Exhibit 10.06 to Current Report on Form 8-K filed with the SEC on February 8, 2006.Investor Registration Rights Agreement dated February 2, 2006 between the registrant and Cornell Capital Partners, LP. Incorporated by reference to Exhibit 10.05 to Current Report on Form 8-K filed with the SEC on February 8, 2006.2004 Stock Option Plan of the registrant. Incorporated by reference to Exhibit 4.1 to Report on Form S-8 filed with the SEC on December 1, 2005.2005 Stock Option Plan of the registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on May 15, 2006.License Agreement, between University of Pennsylvania and the registrant dated as of June 17, 2002, as Amended and Restated on February 13, 2007. Incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-KSB filed with the SEC on February 13, 2007.Sponsored Research Agreement dated November 1, 2006 by and between University of Pennsylvania (Dr. Paterson Principal Investigator) and the registrant. Incorporated by reference to Exhibit 10.44 to Annual Report on 10-KSB filed with the SEC on February 13, 2007.&Non-Exclusive License and Bailment, dated as of March 17, 2004, between The Regents of the University of California and Advaxis, Inc. Incorporated by reference to Exhibit 10.8 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Consultancy Agreement, dated as of January 19, 2005, by and between LVEP Management, LLC. and the registrant. Incorporated by reference to Exhibit 10.9 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Amendment to Consultancy Agreement, dated as of April 4, 2005, between LVEP Management LLC and the registrant. Incorporated by reference to Exhibit 10.27 to Annual Report on Form 10-KSB filed with the SEC on January 25, 2006.Second Amendment dated October 31, 2005 to Consultancy Agreement between LVEP Management LLC and the registrant. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on November 9, 2005.Third Amendment dated December 15, 2006 to Consultancy Agreement between LVEP Management LLC and the registrant. Incorporated by reference to Exhibit 9.01 to Current Report on Form 8-K filed with the SEC on December 15, 2006. Consultancy Agreement, dated as of January 22, 2005, by and between Dr. Yvonne Paterson and Advaxis, Inc. Incorporated by reference to Exhibit 10.12 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504). Consultancy Agreement, dated as of March 15, 2003, by and between Dr. Joy A. Cavagnaro and Advaxis, Inc. Incorporated by reference to Exhibit 10.13 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Consulting Agreement, dated as of July 2, 2004, by and between Sentinel Consulting Corporation and Advaxis, Inc. Incorporated by reference to Exhibit 10.15 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Agreement, dated July 7, 2003, by and between Cobra Biomanufacturing PLC and Advaxis, Inc. Incorporated by reference to Exhibit 10.16 to Pre-Effective Amendment No. 4 filed on June 9, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Securities Purchase Agreement, dated as of January 12, 2005, by and between the registrant and Harvest Advaxis LLC. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on January 18, 2005.Registration Rights Agreement, dated as of January 12, 2005, by and between the registrant and Harvest Advaxis LLC. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on January 18, 2005.Letter Agreement, dated as of January 12, 2005 by and between the registrant and Robert T. Harvey. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on January 18, 2005. Consultancy Agreement, dated as of January 15, 2005, by and between Dr. David Filer and the registrant. Incorporated by reference to Exhibit 10.20 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Consulting Agreement, dated as of January 15, 2005, by and between Pharm-Olam International Ltd. and the registrant. Incorporated by reference to Exhibit 10.21 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Letter Agreement, dated February 10, 2005, by and between Richard Berman and the registrant. Incorporated by reference to Exhibit 10.23 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Employment Agreement, dated February 8, 2005, by and between Vafa Shahabi and the registrant. Incorporated by reference to Exhibit 10.24 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Employment Agreement, dated March 1, 2005, by and between John Rothman and the registrant. Incorporated by reference to Exhibit 10.25 < to Pre-Effective Amendment No. 2 filed on April 8, 2005 to Registration Statement on Form SB-2/A (File No. 333-122504).Clinical Research Services Agreement, dated April 6, 2005, between Pharm-Olam International Ltd. and the registrant. Incorporated by reference to Exhibit 10.26 to Pre-Effective Amendment No. 4 filed on June 9, 2005 to Registration Statement on Form SB-2 (File No. 333-122504). Royalty Agreement, dated as of May 11, 2003, by and between Cobra Bio-Manufacturing PLC and the registrant. Incorporated by reference to Exhibit 10.28 to Pre-Effective Amendment No. 4 filed on June 9, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Letter Agreement between the registrant and Investors Relations Group Inc., dated September 27, 2005. Incorporated by reference to Exhibit 10.31 to Post-Effective Amendment filed on January 5, 2006 to Registration Statement on Form SB-2 (File No. 333-122504).Consultancy Agreement between the registrant and Freemind Group LLC, dated October 17, 2005. Incorporated by reference to Exhibit 10.32 to Post-Effective Amendment filed on January 5, 2006 to Registration Statement on Form SB-2 (File No. 333-122504).Employment Agreement dated August 21, 2007 between the registrant and Thomas Moore. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on August 27, 2007.Employment Agreement dated February 9, 2006 between the registrant and Fred Cobb. Incorporated by reference to Exhibit 10.35 to the Registration Statement on Form SB-2 (File No. 333-132298) filed with the SEC on March 9, 2006.Termination of Employment Agreement between J. Todd Derbin and the registrant dated October 31, 2005. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 9, 2005.Consulting Agreement dated June 1, 2006 between the registrant and Biologics Consulting Group Inc. Incorporated by reference to Exhibit 10.40 to Annual Report on Form 10-KSB field with the SEC on February 13, 2007.Consulting Agreement dated June 1, 2006 between the registrant and Biologics Consulting Group Inc., as amended on June 1, 2007. Incorporated by reference to Exhibit 10.42(i) to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Master Contract Service Agreement between the registrant and MediVector, Inc. dated May 20, 2007. Incorporated by reference to Exhibit 10.44 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Form of note issued in the August 2007 financing. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on August 27, 2007.Letter of Agreement, dated November 21, 2007, between Crystal Research Associates, LLC and the registrant. Incorporated by reference to Exhibit 10.45 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.3Service Proposal O781, dated May 14, 2007, to the Strategic Collaboration and Long Term Vaccine Supply Agreement, dated October 31, 2005, between the registrant and Cobra Biomanufacturing Plc. Incorporated by reference to Exhibit 10.46 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.4Service Proposal, dated September 20, 2007, to the Strategic Collaboration and Long Term Vaccine Supply Agreement, dated October 31, 2005, between the registrant and Cobra Biomanufacturing Plc. Incorporated by reference to Exhibit 10.47 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Consulting Agreement, dated May 1, 2007 between the registrant and Bridge Ventures, Inc. Incorporated by reference to Exhibit 10.48 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Consulting Agreement, dated August 1, 2007 between the registrant and Dr. David Filer. Incorporated by reference to Exhibit 10.49 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Employment Agreement dated February 29, 2008 between the registrant and Christine Chansky. Incorporated by reference to Exhibit 10.50 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Note Purchase Agreement, dated September 22, 2008 by and between Thomas A. Moore and the registrant. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on September 30, 2008.Lease Extension Agreement dated June 1, 2008 by and between New Jersey Economic Development Authority and the registrant. Incorporated by reference to Exhibit 10.55 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Technical/Quality Agreement dated May 6, 2008 by and between Vibalogics GmbH and the registrant. Incorporated by reference to Exhibit 10.57 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Master Service Agreement dated April 7, 2008 by and between Vibalogics GmbH and the registrant. Incorporated by reference to Exhibit 10.58 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Agreement, dated as of December 8, 2008, by and between The Sage Group and the registrant. Incorporated by reference to Exhibit 10.59 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Service Agreement dated January 1, 2009 by and between AlphaStaff, Inc. and the registrant. Incorporated by reference to Exhibit 10.60 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Promissory Note issued to Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, dated November 10, 2003. Incorporated by reference to Exhibit 10.53 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Promissory Note issued to Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, dated December 17, 2003. Incorporated by reference to Exhibit 10.54 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Letter of Intent dated November 20, 2008 by and between Numoda Corporation and the registrant. Incorporated by reference to Exhibit 10.61 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Consulting Agreement dated December 1, 2008 by and between Conrad Mir and the registrant. Incorporated by reference to Exhibit 10.62 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Form of Note Purchase Agreement. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Senior Secured Convertible Note. Incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Senior Promissory Note as amended, between the registrant and Thomas Moore. Incorporated by reference to Exhibit 4.3 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Security Agreement. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Subordination Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Series A Preferred Stock Purchase Agreement dated September 24, 2009 by and between Optimus Capital Partners, LLC and the registrant. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on September 25, 2009.Form of Note Purchase Agreement, entered into in connection with the junior bridge financing. Incorporated by reference to Exhibit 10.61 to Registration Statement on Form S-1 (File No. 333-162632) filed with the SEC on October 22, 2009.Form of Convertible Promissory Note, issued in the junior bridge financing. Incorporated by reference to Exhibit 4.13 to Registration Statement on Form S-1 (File No. 333-162632) filed with the SEC on October 22, 2009.Form of Amended and Restated Senior Promissory Note, between the registrant and Thomas Moore. Incorporated by reference to Exhibit 4.17 to Annual Report on Form 10-K filed with the SEC on February 19, 2010.Amendment to Senior Promissory Note. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K/A filed with the SEC on February 11, 2010.Amended and Restated 2009 Stock Option Plan of the regist< rant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 30, 2010.Form of Stock Purchase Agreement dated May 10, 2010 between the registrant and Numoda Capital Innovations, LLC. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on May 14, 2010.Second Amendment to the Amended and Restated Patent License Agreement between the registrant and the University of Pennsylvania dated as of May 10, 2010. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 3, 2010.Master Agreement, dated June 19, 2009, by and between Numoda Corporation and Advaxis, Inc. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.Form of Project Agreement by and between Numoda Corporation and Advaxis, Inc. Incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.Clinical Trial Services Agreement, dated December 13, 2009, by and between the Gynecologic Oncology Group and Advaxis, Inc. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.7Amendment No. 3, dated as of December 12, 2011, to the License Agreement, between University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.Exchange Agreement, dated as of July 5, 2012, by and between Advaxis, Inc. and Thomas A. Moore. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 11, 2012.7Agreed Order Granting Joint Expedited Motion for Order Approving Settlement of Claim entered by the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida, dated July 24, 2012. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 25, 2012.Stipulation for Settlement of Claim between Socius CG II, Ltd. and Advaxis, Inc., dated July 23, 2012. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on July 25, 2012.Amendment No. 1 to 2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex B to DEF 14A Proxy Statement filed with the SEC on July 19, 2012.Promissory Note issued to JLSI, LLC on July 21, 2012. Incorporated by reference to Exhibit 10.111 to Registration Statement on Form S-1 (File No. 333-183682) filed with the SEC on August 31, 2012.Form of Convertible Promissory Note issued to Dr. James Patton. Incorporated by reference to Exhibit 10.112 to Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-183682) filed with the SEC on September 11, 2012.Form of Convertible Promissory Note issued to JMJ Financial on August 27, 2012. Incorporated by reference to Exhibit 10.113 to Registration Statement on Form S-1 (File No. 333-183682) filed with the SEC on August 31, 2012.Form of Note Purchase Agreement by and between Advaxis, Inc. and Dr. James Patton. Incorporated by reference to Exhibit 10.114 to Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-183682) filed with the SEC on September 11, 2012.Common Stock Purchase Agreement, dated as of October 26, 2012, by and between Advaxis, Inc. and Hanover Holdings I, LLC. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on October 31, 2012.Registration Rights Agreement, dated as of October 26, 2012, by and between Advaxis, Inc. and Hanover Holdings I, LLC. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on October 31, 2012./Order for Approval of Stipulation for Settlement of Claims entered by the Superior Court of the State of California for the County of Los Angeles  Central District, dated December 20, 2012. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on December 28, 2012.Stipulation for Settlement of Claims between Ironridge Global IV, Ltd. and Advaxis, Inc., dated December 19, 2012. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on December 28, 2012.Code of Business Conduct and Ethics dated November 12, 2004. Incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed with the SEC on November 18, 2004.23.1*Consent of Marcum LLP23.2*Consent of McGladrey LLPIPower of Attorney (Included in the signature page of this annual report). INDEXPage Advaxis, Inc.9Reports of Independent Registered Public Accounting Firms F-1 - F-20Balance Sheets as of October 31, 2012 and 2011F-3Statements of Operations for the years ended October 31, 2012 and 2011 and the cumulative period from March 1, 2002 (Inception) to October 31, 2012F-4qStatements of Stockholders Equity (Deficiency) for the Period from March 1, 2002 (Inception) to October 31, 2012F-5Statements of Cash Flows for the years ended October 31, 2012 and 2011 and the cumulative period from March 1, 2002 (Inception) to October 31, 2012F-6!Notes to the Financial StatementsF-8 ADVAXIS, INC.October31, 2012October31, 2011ASSETSCurrent Assets:CashOther Current Receivable-Prepaid expensesOther Current AssetsDeferred Expenses - currentTotal Current AssetsDeferred expenses  long-term8Property and Equipment (net of accumulated depreciation)3Intangible Assets (net of accumulated amortization)9Deferred Financing Cost (net of accumulated amortization) Other Assets TOTAL ASSETS(LIABILITIES AND SHAREHOLDERS DEFICIENCYCurrent Liabilities:Accounts payableAccrued ExpensesBShort-term Convertible Notes and fair value of embedded derivative4Notes payable  Officer (including interest payable)Notes payable  otherTotal Current Liabilities Deferred RentLong-term Convertible NotesCommon Stock Warrant LiabilityTotal LiabilitiesCommitments and ContingenciesShareholders Deficiency:Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at October 31, 2012 and 2011. Liquidation preference of $9,722,570Common Stock - $0.001 par value; authorized 1,000,000,000 shares, issued and outstanding 394,804,165 in 2012 and 250,173,570 in 2011'Promissory Note and Interest ReceivableAdditional Paid-In Capital0Deficit accumulated during the development stageTotal Shareholders Deficiency,TOTAL LIABILITIES & SHAREHOLDERS DEFICIENCY Statement of OperationsYearEnded October31,7Periodfrom March1,2002 (Inception)to October31,20122011Revenue$-Research & Development Expenses!General & Administrative ExpensesTotal Operating expensesLoss from OperationsOther Income (expense):Interest expenseOther Income (Expense)(Loss) on note retirement`Gain on change in fair value of common stock warrant liability and embedded derivative liability"Net Loss before income tax benefitIncome Tax BenefitNet Loss*Dividends attributable to preferred shares#Net Loss applicable to Common Stock,Net Loss per common share, basic and dilutedGWeighted average number of common shares outstanding, basic and diluted: Period from March 1, 2002 (inception) to October 31, 2012PreferredStock CommonStock!Numberof Sha< resof OutstandingAmount Numberofshares ofoutstanding-Promissory Note and Interest ReceivableAdditionalPaid- inCapital7Deficit Accumulated Duringthe Development Stage"Shareholders Equity(Deficiency)Preferred stock issuedCommon Stock Issued.Options granted to consultants & professionalsERetroactive restatement to reflect re-capitalization on Nov. 12, 2004Balance at December 31, 2002+Note payable converted into preferred stock0Options granted to consultants and professionalsNet lossBalance at December 31, 2003!Stock dividend on preferred stockBalance at October 31, 2004;Common Stock issued to Placement Agent on re-capitalizationEffect of re-capitalization*Conversion of Note payable to Common StockCIssuance of Common Stock for cash, net of shares to Placement Agent'Issuance of common stock to consultantsFIssuance of common stock in connection with the registration statementIssuance costsYRestatement to reflect re- capitalization on Nov. 12, 2004 including cash paid of $44,940Balance at October 31, 2005*Options granted to employees and directors'Conversion of debenture to Common Stock3Issuance of Common Stock to employees and directorsBalance at October 31, 2006Common Stock issuedOffering Expenses/ptions granted to consultants and professionals<Warrants issued on conjunction with issuance of common stockBalance at October 31, 2007Common Stock Penalty SharesWarrants issued to consultantBalance at October 31, 2008-Common stock issued upon exercise of warrants#Warrants classified as a liability!Issuance of common Stock Warrants0Options granted to professionals and consultants3Issuance of common stock to employees and directors Net IncomeBalance at October 31, 2009Preferred Stock issued3Common stock issued upon conversion of Bridge NotesCommon stock issued to Numoda1Common stock issued to University of Pennsylvania.Common stock issued to employees and directors'Common stock issued to former employees!Issuance of common stock warrantsBalance at October 31, 2010Preferred Stock redeemedOptions granted to consultants-Common stock issued upon exchange of warrants5Common stock issued upon conversion of May 2011 Notes&Common stock issued to former employee"Common stock issued to consultants/Reclassification of warrant liability to equityRReclassification of Embedded Derivative Liability to Beneficial Conversion Feature$Interest on Optimus Notes Receivable@Reclassification of interest receivable to-date on Optimus notesBalance at October 31, 2011:Stock compensation to employees, directors and consultantsBIssuance of shares upon conversion of convertible promissory notesQFair value of equity warrants issued in connection with Rodman May 2012 Financing0Common stock issued upon conversion of JMJ Notes=Common stock issued to directors as earned stock compensation/Issuance of shares to employees under ESPP PlanPIssuance of shares to investors as part of the May 2012 Debt for Equity Exchange8Issuance of shares under Numoda Stock Purchase Agreement1Issuance of shares under JMJ Settlement Agreement Exchange of Platinum Bridge NoteIssuance of shares to SociusBalance at October 31, 2012 Statement of Cash Flows PeriodfromMarch12002 Yearended(Inception)to October31,OPERATING ACTIVITIESKAdjustments to reconcile net loss to net cash used in operating activities:CNon-cash charges to consultants and employees for options and stock(Amortization of deferred financing costs8Amortization of discount on convertible promissory notesImpairment of intangible assetsNon-cash interest expenseB(Gain) Loss on change in value of warrants and embedded derivativeWarrant ExpenseSettlement Expense$Employee Stock Purchase Plan ExpenseValue of penalty shares issuedDepreciation expense#Amortization expense of intangiblesWrite off of intangible assetsInterest IncomeLosson note retirement,Change in operating assets and liabilities :'(Increase) decrease in prepaid expensesdecrease in grant receivable"(Increase) in other current assets(Increase) in other assets((Increase) decrease in deferred expenses1Increase in accounts payable and accrued expenses'(Decrease) increase in interest payableIncrease in deferred rent%Net cash used in operating activitiesINVESTING ACTIVITIES.Cash paid on acquisition of Great Expectations"Purchase of property and equipmentCost of intangible assets%Net cash used in Investing ActivitiesFINANCING ACTIVITIESProceeds from convertible notesRepayment of convertible notes1(Increase) decrease in deferred offering expenses&Cash paid for deferred financing costsProceeds from notes payableProceeds from Officer LoanRepayment of Officer LoanDeferred Investment Funds+Net proceeds of issuance of Preferred Stock#Payment on cancellation of Warrants&Proceeds from the exercise of warrants(Net proceeds of issuance of Common Stock)Net cash provided by Financing ActivitiesNet increase (decrease) in cashCash at beginning of periodCash at end of period2 Supplemental Disclosures of Cash Flow InformationCash paid for InterestF Supplemental Schedule of Noncash Investing and Financing Activities Twelve monthsended October 31,7Periodfrom March1,2002 (Inception)to October 31,&Equipment acquired under notes payableCommon stock issued to Founders?Notes payable and accrued interest converted to Preferred Stock!Stock dividend on Preferred Stock5Accounts Payable from vendors settled in Common Stock;Accounts Payable from consultants settled with Common StockKNotes payable and embedded derivative liabilities converted to Common Stock-Intangible assets acquired with notes payable,Intangible assets acquired with common stockbDebt discount in connection with recording the original value of the embedded derivative liabilityEAllocation of the original secured convertible debentures to warrants@Allocation of the warrants on convertible notes as debt discountMCancellation of Note Receivable in connection with Preferred Stock Redemption7Note receivable in connection with exercise of warrants,Common stock issued in exchange for warrants;Warrants Issued in connection with issuance of Common Stock>Warrants Issued in connection with issuance of Preferred StockAsofOctober31,Warrants Stock Options0Convertible Debt (using the if-converted method)Total9March1,2002 (dateof inception)to October31, 2012Net Loss as reported=Add: Stock based option expense included in recorded net lossQDeduct stock option compensation expense determined under fair value based methodAdjusted Net LossLaboratory EquipmentAccumulated DepreciationNet Property and Equipment 5. INTANGIBLE ASSETSLicensePatentsTotal intangiblesAccumulated AmortizationIntangible AssetsYear ended October 31,20132014201520162017 6. ACCRUED EXPENSES:Salaries and other compensationClinical TrialVendors ConsultantsFinancing costsLegalInterest PayableOther October 31, 2012October 31, 2011May 2011 Note Financing$ October 2011 Note FinancingDecember 2011 Note Financing May 2012 Note Financing Bridge Notes JMJ FinancialHanover Holdings NoteMagna Chris FrenchAsherYvonne Paterson James PattonTotal Convertible NotesUnamortized discountDerivative Liability 10. DERIVATIVES Description PrincipalOriginal Issue DiscountWarrant LiabilityEmbedded Derivative Liability#Total Valuation at October 31, 2010&Issuance of November 2010 Bridge Notes&Exchange of November 2010 Bridge Notes%Issuance of January 2011 Bridge Notes Note PayoffsIssuance of WarrantsAccreted InterestExercise of Warrants Change in FV#Total Valuation at January 31, 2011 Issuance of Q2 2011 Bridge Notes2Issuance of Long-term Convertible Promissory Notes!Total Valuation at April 30, 2011 Issuance< of Q3 2011 Bridge NotesIssuance of May 2011 Notes0Additional warrants issued to Bridge Note holderExchange of Bridge NotesConversion of Bridge NotesConversion of May 2011 Notes,Exchanges/Exercises of October 2007 Warrants Total Valuation at July 31, 2011Issuance of October 2011 Notes/Reclassification of Warrant liability to EquityExchange of Warrants#Total Valuation at October 31, 2011Issuance of December 2011 Notes Conversion of October 2011 NotesPartial Note Repayments4Conversion of Long-term Convertible Promissory Notes#Total Valuation at January 31, 2012Exchange of Bridge Notes!Conversion of December 2011 Notes!Total Valuation at April 30, 2012Issuance of May 2012 NotesCDebt for Equity Exchange: May and October 2011, December 2011 Notes&Debt for Equity Exchange: Bridge NotesJuly 2012Exchange of WarrantsJMJ Settlement AgreementJMJ Note Conversions Total Valuation at July 31, 2012Issuance of Patton NoteIssuance of French NoteIssuance of Paterson Note"Issuance of Hanover September NoteIssuance of Asher Note Issuance of Hanover October NoteIssuance of JMJ NoteAssignment of Notes to Magna+New Magna Note (result of above assignment)Magna ConversionsJAdditional warrants issued due to investors due to anti-dilution provision#Total Valuation at October 31, 2012 WarrantsTypeExercise PriceExpirationDateTypeofFinancing Exchange warrants-nonexercisable October 2014July 2012 Warrant ExchangesCommon Stock Purchase WarrantMay 2015#May 2011 Convertible Debt FinancingOctober 2014-October 2015'October 2011 Convertible Debt FinancingJanuary 2015-January 2016(December 2011 Convertible Debt FinancingMay 2017#May 2012 Convertible Debt Financing $0.1495-0.17January 2013-April 2015N/AVendor & OtherMay 2014  May 2017,Placement Agent  Convertible Debt Financing 0.0530-0.15October 2015-August 20174August  September 2012 Convertible Promissory Notes Subtotal:TBD (1) April 2014%Preferred Stock Agreement (4/04/2011) Grand TotalAugust  October 2012#2007 Securities Purchase Agreement August 2012August 2007 NotesMay 2014 $0.15 - $0.17January 2013  April 2015 August 2014Executive Officer $0.15-$0.1952 February 2012May 2014 - November 2015Subtotal-Optimus Preferred Stock Agreement (4/04/2011) 10/31/2012 10/31/2011Exercise Price: 0.053-0.17 0.15-0.17 Stock PriceExpected term: 81-1736 days 289-1219 days Volatility %66.51%-146.78%60.23%-163.40%Risk Free Rate: .09%-.72%.09-.56% 11. STOCK OPTIONS:Shares"Weighted Average Exercise Price7WeightedAverage Remaining ContractualLifeIn YearsAggregate IntrinsicValue"Outstanding as of October 31, 2010GrantedCancelled or Expired"Outstanding as of October 31, 2011"Outstanding as of October 31, 2012(Vested & Exercisable at October 31, 2012 YearEndedOctober31, 2012October31, 2011Expected volatility143.00%150.44% Expected Life 10.0 yearsDividend yieldRisk-free interest rate2.10%3.50%Forfeiture Rate4.4%4 Rothman Employment Agreement and Option Agreements.October 31, 2012October 31, 2011FederalCurrentDeferredState and LocalChange in valuation allowanceIncome tax provision (benefit) Years EndedDeferred Tax AssetsOctober 31, 2012October 31, 2011Net operating loss carryoversStock-based compensationOther deferred tax assetsTotal deferred tax assetsValuation allowance.Deferred tax asset, net of valuation allowanceDeferred Tax LiabilitiesValuation of warrantsOther deferred tax liabilitiesTotal deferred tax liabilities"Net deferred tax asset (liability)Yearended October31, 2012Yearended October31, 2011US Federal statutory rate(34.00)%(State income tax, net of federal benefit,Fair value of common stock warrant liabilityDeferred tax adjustmentOther permanent differences12.6%(2.9(4.5 15. FAIR VALUELevel1Level2Level3lCommon stock warrant liability, warrants exercisable at $0.053 - $0.17 from October 2012 through August 2017$$Embedded Derivative Liability$Short term Convertible Notes PayableMay 2012 Notes-Hanover PIPE Notes  September & October 2012Magna Exchange Note Asher NoteFrench, Patton & Paterson NoteswOther Short-term Notes Payable  not measured at fair value (net of debt discount of $4,541 related to unamortized OID):Short-term convertible Notes and FV of Embedded DerivativepCommon stock warrant liability, warrants exercisable at $0.15 - $0.1952 from February 2011 through November 2015UEmbedded derivative liability, convertible at $0.15 from August 2011 through May 2012" Common stock warrant liability: October 31, 2012.Beginning balance at October 31, 2011 and 2010#Exercises and Exchanges of warrantsChange in fair value$Balance at January 31, 2012 and 2011Exercises of warrantsExchanges of warrants"Balance at April 30, 2012 and 2011)Reclassification of liabilities to equity'Debt for Equity Exchange: Bridge NotesJuly Warrant Exchanges&Exercises and/or Exchanges of warrants!Balance at July 31, 2012 and 2011Exchange of warrants?Issuance of additional warrants due to anti-dilution provisions$Balance at October 31, 2012 and 2011October 31, 2012October 31, 2011BIssuance of embedded derivatives associated with convertible notesNote Conversions and PayoffsDebt for Equity Exchange(190,449 (1,766,161Ending balanceIssuance of notesIssuance of C/S warrantsChanges in fair valueHanover PIPE NotesConversions to common stockIssuance of warrantsFebruary 13, 2013/s/Thomas MooreName: Thomas MooreTitle: Chief Executive Officer/s/Mark J. RosenblumName: Mark J. RosenblumCTitle: Chief Financial Officer, Senior Vice President and SecretaryE AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Date: February 13, 2013/s/ Thomas MooreName: Thomas MooreTitle:Chief Executive Officer/s/ Mark J. RosenblumMark J. Rosenblum<Chief Financial Officer, Senior Vice President and Secretary"p kdpcc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )}  ,@,,,,, ,            ~ OQ?~  C ~ / ~ G~ '~  [ ~ / ~ ?Q?~  g Q? ~ # ~  ~ G ~ 7         PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , , ,,,,,,,,,~   ffffff$@  ~   ~ C  ~ k  ~  ~  ~  ~   ~  ~  = ףp=$@ (\B$@ ~  ~  PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , ,,,,,,,,~  ~  ~  ~   ffffff$@  Qk$@ q= ףp$@ ~  ~   ~  !~   "~  #~  $PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , , ,,,,,,,,~  %~  &~  '~ # (~ ' )~ + *~ / +~ 3 ,~ 7 -~ ; .~ ? /~ C 0~ G 1~ K 2PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , , ,,,,,,,,~ O 3~ S 4~ W 5~ [ 6~ _ 7~ c 8~ g 9~ k :~ o ;~ s <~ w =~ { >~  ?~  @PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} !,,,, , ,,,,,,,,,,~  A~  B~  C~  D~  E~  F~  G~  H~  I~  J~  K~  L~  M~  N~  O ,~  PPH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} (,,,, , , ,,,,,,,,,,~j4$@ Qh|?5$@ R(\5$@ SʡE6$@ T X96$@ U K7$@ V +7$@ W~  XF8$@ YMbX9$@ Z`"9$@ [|?5^:$@ \{G:$@ ]Zd;$@ ^Cl;$@ _#~j<$@ `!,#,%,',~ !  !a #b #c %d %e~ '% 'fPHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } ,@,,,, , ,,, g h i j k l m n o p q r s t u PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } ,,@ @,,,,, , , , ,,,,,,,,,,,,,,,,, v w x y z {~ ~ jB | }~ r) ~~ ~ I ~ ~ " ~ 4 } ~ 6~ b ~ ~ @<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} `} }  } }  }  } }  ,@ @ , , , , , , , , , , , , , , , , ,,,                  ~  q  ~ :~ ~  J ~ 5[~ ~-~  zg ~ ~ R~  ~ 6%~ d~   ~ ~ f2~ Um ~ ~ /~  ~ wz~ ~  Je ~ J~ S~  Q ~ ( ~ R~~  3 ~ *~ B)~  ru ~ &S~ ~  fQ ~ *-~ ]~  * ~ (~ ~  >  ~   ~   ~ *pL~ %5     PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Y} }  } }  }  } } }  } }  } }  } }  } }  } { ,@, @ ,, , , , , , , ,, ,, , ,, ,,, , , , , , ,                   ~ j5~ W~ W ~  q~ ~ b ~ ~  ~ ~  ~ ~ "~ n~ ~ d ~ n~  ~  ~ ~ v ~ ~ ~   ~ ~  ~ >y~ >y ~ b~ ~~  ~  n~ ~ 2~ H~  ~  ~ ~ RR ~ (~ ( ~ S~ S ~  ~ RR~  ~  n~ ~ ~ Ú~ b> ~  b-~  ~ > ~  b-~  ~ > ~ r~ r ~  e~ b!~ :K%~ l% ~  )~ ~ ~   ~  j#~ . ~ $ ~ - ~  ~ b~ %~ + ~ ~  ,! ," ,$ ,% ,& ,' ,( ,) ,* ,, ,- ,. ,/ ,0 ,1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,: ,; ,< ,= ,> , ~ ȑ~ ȑ !~ !"~ !" "~ " r2~ "L"~ "><"~ "J,"~ "^j" $~ $~ ~ $~ %~ %_~ %_ &~ & k~ &~ &3~ &O '~ ' ~ '~ 'U~ '*Y (~ ( B!~ (~ (}~ (j )~ )B~ )B *~ * B ~ *t~ *i~ *D~ * ,~ , ~ ,r~ ,*8~ ,< -~ -w~ -w .~ .d~ .d /~ / ~ / 0~ 0 ꫩ~ 0l~ 0 <~ 0* = 1~ 1 k~ 1~ 1z~ 1" 2~ 2 #C~ 22~ 2x ~ 2J 3~ 3:[~ 3:[ 4~ 4.1j~ 4.1j 5~ 5 f;~ 5֖5~ 5r5~ 5u5~ 5.5 6~ 6 6 ~ 6R~ 6: 6}~ 6 7~ 7=~ 7= 8~ 8j~ 8j 9~ 9~ 9 :~ : <~ :~ :60~ :? ;~ ; c ~ ;j~ ;~ ;b <~ <zd~ <zd =~ =zh~ =zh >~ > U~ >>~ >z;>~ >2>~ >>@ ,A ,B ,C ,E ,F ,G ,H ,I ,K ,L ,M ,N ,O ,P ,Q ,R ,S ,T ,U ,W ,X ,Y ,Z ,[ ,\ ,] ,^ ,_ , @~ @ ~j~ @3~ @r~ @ A~ A~ A B~ B^%~ B^% C~ C~ C E~ E~ E~ E F~ F ~ F~ Fv~ F G~ G q~ G(~ G~ G., H~ Hr8~ Hr8 I~ I ~ II~ IJ.I~ I I~ I¶?I K~ KV K}~ KĠ~ KĠ L~ L [~ L~ L bu~ L'r~ LvV M~ M~ M N~ N "ˬ~ N~ N~ N O~ O ~ O6~ O2$~ OP$ P~ P f~ P~ P?~ PE Q~ Q -~ Q ~ Q~ Q  R~ R j~ RF~ R R} S~ SJq*~ SB T~ Tbl~ Tbl U~ UV U}~ U F;/~ UV U~ U buU~ UbU~ UvU~ UxU W~ W W}~ W*Tf~ W*Tf X~ Xz X}~ X7~ XI@~ X Y~ Y z~ Y*g~ Y(n~ Y`~ Y~ Z~ Z+~ Z+ [~ [~ [ \~ \ D~ \~ \ln~ \vo ]~ ] }d~ ]F[~ ]D]~ ]6] ^~ ^ ~ ^~ ^\~ ^>" _~ _ :-~ _ ~ _.~ _` ,a ,b ,c ,d ,e ,f ,g ,h ,j ,l ,m ,n ,o ,p ,q ,r ,s ,t ,u ,v ,w ,x ,y ,z , `~ ` VX~ `6~ `~ `B  a~ aA~ aA b~ b"~ b" c~ ca ~ ca d~ d2~ d2 e~ ej~ ej f~ f~ f g~ g ~ g  b;~ gDg~ g*X~ g*~ gP~ g h~ hnE~ hnE j~ j ?A~ jv~ j"@~ jB l~ l~ l m~ m &~ m*~ m~ m! n~ n za~ n~ n ~ n o~ o ,~ o~ o$(~ o( p~ p B=~ p~ p~ p q~ q V~ q~~ qJh~ qn r~ r  ~ r>~ r~ r s~ s 3 ~ s8~ s6n~ s9q t~ t~ t= t} u~ u ~ ub~ u"PS~ u:T v~ v ~ v6~~ v@~ vNA w~ w~ w x~ x f~ xw~ xVl~ x>$n y~ y&S~ y&S z~ z ~ z  ^~ zz~ z*z~ z8U z~ zz~ zrz5     """"""""55555555>>>>>>>>IIIIIIIIUUUUUUUUUUggzzzzzzzzzzPH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} K} }  } } }  }  } } ; ,@ , , , , , , , , , , , , , , , , , , , , , , , ,, , , , ,     ! !    ! !    ! ! !! !!  !  ! ! ! ! !  !  ! !! !!  ! !      ~ &S ~  ~ fQ     ~ nE~ j0~ :/ ~  }~ " ~ ^~ .s~  m  } }~   ~ ~ ~   ~ Lk~ ^~  " ~ Z~  "~  ". ~ , }~  , ~  }~    } }~  r ~ B~ ڻ~   ~  ~ ~  S- ~ ~    }~ .~  . ~ .~ n,~  <  ~ r~ 6~  l  }~   } ~ ޢ~ N~  *  ~ j~  F ,! ," ,# ,$ ,%,& ,' ,( ,) ,*,+ ,, ,- ,. ,/ ,0 ,1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,: , !~ . ~ ~ R !"~ !]~ !~ ! 3 "#~ "N~ "N~ "  #$~ #n{~ #~ # K $%~ $+~ $,~ $ & %& &' &}~ & A '(~ 'd '}~ ' ; ()~ (c~ (j~ ( nm; )*~ )~ )j~ ) ) *+ +,~ +~X~ +~ + " B ,-~ ,~ ,֣~ , Y -.~ -B7~ -~ -  ./ .}~ .by~ . NS /0~ /BB /}~ / BB 01~ 0~ 0b~ 0 *X 12~ 1"~ 1a~ 1  23 2} 2 } 34 3}~ 3BQ~ 3   45 4} 4}~ 4 a 56~ 5!~ 5&9B~ 5 :e 67 6}~ 6  78~ 7!~ 7v:p~ 7  89~ 8:~ 8O<~ 8  9:~ 9jB~ 9v 9 } :;~ ::~ :jB:~ : :           :::::: PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  ,@ @ , , <           =~ <~  ~  0 J    PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} b}  ,@ @ , , , , , , , , , , , , , , , , , , > ?  @       A  ~  2  B  ~    C  ~    D  ~    E~ ]   ~ ]  F~    ~ 6  G~ &9 ~ = ~ vN  H    ~   I    ~ E  J~ "~ ~    K  ~     L~ "~ }/~  :7  M ~ "E~  "E  N ~ ב~   >b  O~ 2: ~  2:  P~  ~  ~{  Q  ~   9                        PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 0} }  } }  } ,,,,,, R   S~ r4~ 3 T~ Ԯ ~ R U~ D~ zs V~ L*~ >6PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Q} }  }  @,,,, W X~ fQ Y~ r Z~ B [~ PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  @,,, w x \~ z~ b  ]~ Z7~  ^~  2PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,@ @,,,,, _ w x `~ b'~ b' a~ &ړ~ > b~ ~ f c~ j~  d~ R~ R:PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } ,,,,,, e f~  g~  h~  i~  j~ PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,@ @,,,,, , , , , k w x l~ =/~ i  m~ Rr~  n~ " } o~ "~ " p~  } q~  ~ * r~  } s~ ҄~ ҄~ uS ~ : :  PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,@ @,,,,, , , , , ,,,, t u v w x~ z  y~ "~ Q z~ b  { |~ f# { }~ zV ~ Vp+ ~~ }~ " ~ $ { ~ zT { ~ z { ~ ~2 { ~ U { ~  { ~ "~ >6o*PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,, ~ ~   {~ 9~ .~ RYPH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} J} }  } }  }  } } }  } U,@ @,,,,, , , , , ,,,, ,, ,,,,,, ,,,, ,         ~  o/~ V~   ~  ~ 8~ ~  ~ 2* ~ ^ ~ ^ ~  N~  ~ 6~ V~  › ~  ~  ~ + ~  ~  ~ ~  ~ y~ 6W~ ~  ~ ~ ~  Zf~ Z ~ ;& } ~ A~ £ ~  ↶ ~ *u ~   ~  r,~ . ~ ~ ^r~  : ~ R@ ~ ַ~ ~  M~ N ~ ~ ^  }~  ~ d~ u ~  b8 ~ }~ }~ ) ~ ~  ~ ~  ~  ƍ ,!,",#,$,%,&,',( ,) ,*,+,,,-,.,/,0,1,2,3 ,4,5,6,7 ,8,9,: ,;,<,=,> ,?, ~ > !~ ! v__~ !C} "~ "No"~ "P~ " rj~ "RB #~ #~ #  # }~ #J8 $~ $} %~ %F &~ &v~ &z[ '~ '2~ 'A (~ (  )~ ) 1 *~ *< +~ + r@{~ + ,~ ,#,~ ,]O~ , ~~ ,9 -~ -7K~ -  - }~ -" .~ .b .} /~ /~ /* 0~ 0R~ 0 1~ 1 2~ 2 3~ 3 Ң 4~ 4~ 5~ 5 R~ 5 6~ 6.66~ 6>6~ 6 `Q6 ~ 6A-6 7~ 76; 7 } 8~ 8B~ 8 9~ 9R~~ 9n1 :~ :  ;~ ;> <~ < 6ts~ <jC =~ =N=~ ==~ = = ~ =Vh= >~ >/:~ > " ?~ ?~ ?"~ ?j@ ,A ,B,C,D,E,F,G ,H ,I ,J,K,L,M,N,O,P,Q,R ,S,T, @~ @~ @ ʵ A~ A  B~ B C~ C~ D~ D E~ E  ~ E F~ Fb'jF~ Fn~ F EM~ Fb! G~ G~ G  H~ H~ H VG I~ I~ I J J~ JR K~ K2Q L~ LR M~ M N~ N O~ O.k P~ P Q~ Q R~ R Z S~ S n~ S T~ T OT~ TF~ T b T}   "",,666666 66====== ==FFTTPHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } } } } 4}  ,@ ,@ , , , , , , , , ,,, ,,         ~ ?~ {K     ~ ?~ q     ~ ?~ ƷX     ~ ?~      ~ ? ~ Ɗ     ~   } ~ ? ~    ~ ? ~      ~ V    ~ r%  ~      !!~ r4z     PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } } } } -}   ,@ , , , , , , , , , , ,        ~ ?~ ,:     ~ ?~ f     ~ ?~      ~ ?~ ZR      ~ V;e    } ~ ?~ Bj      ~ G     ~ ? ~ 0   ! !~ $   ~    ! !~ 3 j     PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } } }  ,,,, , ,       ףp= ?@5^I ?         PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} (} }  } }  }  } } }  }  ,@ @,,,,, , , , ,             ~ qO~ C~   ~ ~c ~ B3~ 3 ffffff"@~   } }  } } ~ R~ C~   ~ l ~ .~ ?~ & } ~ ~ +~  } ~ Ԯ ~ C } ~ f~ C ~   Z     PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } , @,,,,,                 ~ ~       "PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,@ @,,,,, , , ,        ~ 2~  #  ~ v~  ~ *~  ~ @~ S ~ v ~  :  PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} .} }  } }  } ,,,,,,,, , , ,,,,   ! " #   $~  ~  %~ ^nt~ Y &~ zx:~ Z '~ ʊ~ v (~ F~ .,x )~ vb ~ 4  * + }~ .: ,~ ~  -~ ~  .  z  PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,} }  } } }  } }   @, ,,,,,, , / 0   1 2 3 2 3 4~ " 5~ " 6"fffffC ~ Әfffff0@ 7~ " 8  9 3 : 3"PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } } } ,@, ,, ; " < =  >  V ?  @~ b~  b  A }B  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  }  ,, ,,,,,, , "      B      C  @~ f#~  f#  D~  $ ~ $ E~  zT ~ zT F~  ~2  ~ ~2 G~  b  ~ b  H~  I~ V{         PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } ,, ,, # < =  >  V      J  @~ ~~  ~  K~  9 ~ 9j     PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ?} }  } }  } ,@ @,,,,, , , , ,,,,,,,,,,,,,,, L M v N~ ~~   }~ ^$ O~ Ң~  P~ R~  Q~ `Q~   }~ : R }~  S~  } P~ 6ts~ r, T~ ~ : ~ "~  U } V~ ʵ } W~  } X }~ ƍ P~  ~ v__ Y~ EM~ rj ~ 4 }  }~  Z }~ 1 [~ Z } P~ n~ r@{ \~ b~ ~J PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} B} }  } }  }  @,,,,,, ] ^ N~ 9~  _~ "~  `~ 2~ @ a~ j b P~ R c d ~ 92PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }   @,,,, , C   e~ b) f~ 6 g~ & ~ f#  PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }   @,,, h  e~ , g~ ~ $PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  @,,,, , , ,, E  e~ .k i~  g~ ~ zT F e~ 2Q g~ N~ ~2 PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } ,,,,, G e~ b j~ j g~ B~ b  PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } ,,,, k l m nPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} C} ,,,, k o p qPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } ,@,,, r s t u v w xPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } <} ,@,,, r s y u z w {PH0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@޿ @޿ ՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookBCompObjIOle SummaryInformation(DocumentSummaryInformation8h